Assuntos
Medicamentos Biossimilares/uso terapêutico , Medicamentos Biossimilares/efeitos adversos , Medicamentos Biossimilares/economia , Região do Caribe , Análise Custo-Benefício/legislação & jurisprudência , Aprovação de Drogas/economia , Aprovação de Drogas/legislação & jurisprudência , Substituição de Medicamentos/economia , Medicamentos Genéricos/efeitos adversos , Medicamentos Genéricos/economia , Medicamentos Genéricos/uso terapêutico , Patentes como Assunto/legislação & jurisprudência , Resultado do Tratamento , Estados Unidos , United States Food and Drug Administration/legislação & jurisprudênciaRESUMO
The use of antidepressant in depressive illness results in a reduction of suicidal attempts and deaths due to suicide, conditions that are generally present in this disorder. Recently, the Federal Drug Administration (FDA) prohibited the use of antidepressants during childhood and adolescence. This decision was based on a supposed increase in suicidal thinking in these age groups. However, the evidence came from flawed clinical studies, some of them not even published, in which no significant differences were observed when compared to placebo. It is not possible to ascribe a direct responsibility to antidepressants, because depression, by definition, has suicidal ideation. On the contrary, the reduction of suicidal rates supports the effectiveness of these medications.